{"id":543,"date":"2015-05-06T03:11:33","date_gmt":"2015-05-06T03:11:33","guid":{"rendered":"http:\/\/hfhpulm.com\/info\/?p=543"},"modified":"2016-04-21T18:37:05","modified_gmt":"2016-04-21T18:37:05","slug":"ipf-drug-therapy","status":"publish","type":"post","link":"https:\/\/hfhpulm.com\/info\/?p=543","title":{"rendered":"IPF Drug Therapy"},"content":{"rendered":"<p>Decision for pirfenidone and nintedanib: For patients with mild or moderate IPF based on pulmonary function tests who do not have underlying liver disease<br \/>\n-Current data are insufficient to direct a firm choice between pirfenidone and nintedanib,<br \/>\n-diarrhea and liver function test abnormalities with nintedanib versus nausea and rash with pirfenidone<\/p>\n<p>2. <a href=\"http:\/\/hfhpulm.com\/info\/wp-content\/uploads\/2015\/05\/Nintedanib-Pirfenidone-comparison-slide.pptx\">Nintedanib &amp; Pirfenidone comparison slide<\/a><\/p>\n<p>3. Counseling: Neither medication offers more than possible slowing of progression of disease or improvement in dyspnea on exertion<\/p>\n<p>4. Neither medication has been tested in advanced disease or in patients with pulmonary hypertension<\/p>\n<p>5. Drug therapy research trials are still available (taking pirfenidone or nintedanib may not exlude patients from these studies)<\/p>\n<p><!--more--><\/p>\n<p><span style=\"text-decoration: underline\"><strong>Nintedanib (Ofev)<\/strong><\/span><\/p>\n<ul>\n<li>General:\u00a0\u00a0\u00a0 <a title=\"Main OFEV page\" href=\"https:\/\/www.ofev.com\/\">https:\/\/www.ofev.com\/<\/a><\/li>\n<li><a href=\"https:\/\/hcp.ofev.com\/_assets\/pdf\/NIN631218CONS_OFEV_Prescription_Form.pdf\">General prescriber info<\/a>:<\/li>\n<li><a href=\"https:\/\/www.ofev.com\/assets\/pdf\/NIN631216CONS_HUB_Patient_Opt_In_Form.pdf\">Patient consent for resources:<\/a>\u00a0 <strong>(patient signature required)<\/strong><\/li>\n<li>Monitoring:\u00a0 Conduct liver function tests (ALT, AST, and bilirubin) prior to treatment with OFEV, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.<\/li>\n<li>Other side effects: diarrhea (smoking may decrease systemic exposure to medication), see website for more details<\/li>\n<li>Patient support\/finance:\u00a0 <a title=\"Patient info, support\" href=\"https:\/\/www.ofev.com\/assets\/pdf\/NIN631216CONS_HUB_Patient_Opt_In_Form.pdf\" target=\"_blank\">https:\/\/www.ofev.com\/assets\/pdf\/NIN631216CONS_HUB_Patient_Opt_In_Form.pdf<\/a><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><strong>Pirfenidone (Esbriet)<\/strong><\/span><\/p>\n<ul>\n<li>General:\u00a0 <a title=\"Esbriet main page\" href=\"https:\/\/www.esbriethcp.com\/\">https:\/\/www.esbriethcp.com\/<\/a><\/li>\n<li>Prescriber form\/patient enrollment in CareConnect:\u00a0\u00a0\u00a0\u00a0 <a title=\"prescriber form esbriet\" href=\"http:\/\/www.esbrietcareconnect.com\/downloads\/Esbriet_Patient_Enrollment_Form.pdf\u00a0\" target=\"_blank\">http:\/\/www.esbrietcareconnect.com\/downloads\/Esbriet_Patient_Enrollment_Form.pdf\u00a0<\/a><strong>\u00a0\u00a0 (patient signature required)<\/strong><\/li>\n<li>Patient auth form (look into financial assistance):\u00a0\u00a0\u00a0 <a title=\"Esbriet Patient Auth Form\" href=\"http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Authorization_Form_English.pdf&lt;strong&gt;\u00a0&lt;\/strong&gt;\" target=\"_blank\">http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Authorization_Form_English.pdf<\/a><strong><a title=\"Esbriet Patient Auth Form\" href=\"http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Authorization_Form_English.pdf&lt;strong&gt;\u00a0&lt;\/strong&gt;\" target=\"_blank\">\u00a0<\/a>\u00a0 (patient signature required)<\/strong><\/li>\n<li>Other resources:\u00a0 <a title=\"Esbriet provider info\" href=\"http:\/\/www.esbrietcareconnect.com\/healthcare-professional\/resources\/\" target=\"_blank\">http:\/\/www.esbrietcareconnect.com\/healthcare-professional\/resources\/<\/a><\/li>\n<li>Monitoring: Conduct liver function tests (ALT, AST, and bilirubin) prior to initiating Esbriet, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary.<\/li>\n<li>Other side effects: photosensitivity, diarrhea<\/li>\n<li>Patient info on initial process:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a title=\"Esbriet patient info on initial process\" href=\"http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Esbriet_CareConnect_Tear_Sheet.pdf\" target=\"_blank\">http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Esbriet_CareConnect_Tear_Sheet.pdf<\/a><\/li>\n<li>Patient info on Esbriet:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <a title=\"Esbriet patient support\" href=\"http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Esbriet_CareConnect_Brochure.pdf.pdf\" target=\"_blank\">http:\/\/www.esbrietcareconnect.com\/downloads\/Patient_Esbriet_CareConnect_Brochure.pdf.pdf<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Decision for pirfenidone and nintedanib: For patients with mild or moderate IPF based on pulmonary function tests who do not have underlying liver disease -Current data are insufficient to direct a firm choice between pirfenidone and nintedanib, -diarrhea and liver function test abnormalities with nintedanib versus nausea and rash with pirfenidone 2. Nintedanib &amp; Pirfenidone [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[84,80,81,83,82,85],"class_list":["post-543","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-esbriet","tag-ipf","tag-ipf-drug","tag-nintedanib","tag-ofev","tag-pirfenidone"],"modified_by":"Jennings","_links":{"self":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=543"}],"version-history":[{"count":14,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/543\/revisions"}],"predecessor-version":[{"id":945,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=\/wp\/v2\/posts\/543\/revisions\/945"}],"wp:attachment":[{"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hfhpulm.com\/info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}